&nbsp;

ABVD.pdf

Sep 2020

Document

ABVD-FR.pdf

Sep 2020

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

ACAL+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded),

oBINutuzumab (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

ACAL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Document

tomMcHughProfile.png

Dec 2020

Regimen

ALPEFLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant,

alpelisib (Unfunded)

Quick Link(s):

Regimen Monograph

Jul 2023

Tumeurs neuroendocriniennes (TNE)

Document

TobaccoWiseFNIMBrochureMetis.pdf

Jan 2021

Document

TobaccoWiseFNIMBrochureMetis-FR.pdf

Jan 2021

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Feb 2021

Regimen

TRAS

Cancer Type:

Gynecologic,

Endometrial

Intent: Palliative, Curative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer

Drugs Used:

trastuzumab